AstraZeneca PLC Valuation
| ZEG Stock | 127.55 1.10 0.87% |
At this time, the firm appears to be overvalued. AstraZeneca PLC shows a prevailing Real Value of USD121.39 per share. The current price of the firm is USD127.55. Our model approximates the value of AstraZeneca PLC from analyzing the firm fundamentals such as Profit Margin of 0.07 %, current valuation of 228.75 B, and Return On Equity of 0.0863 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that AstraZeneca PLC's price fluctuation is very steady at this time. Calculation of the real value of AstraZeneca PLC is based on 3 months time horizon. Increasing AstraZeneca PLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
AstraZeneca PLC's intrinsic value may or may not be the same as its current market price of 127.55, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 127.55 | Real 121.39 | Hype 126.45 |
The intrinsic value of AstraZeneca PLC's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AstraZeneca PLC's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AstraZeneca PLC helps investors to forecast how AstraZeneca stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AstraZeneca PLC more accurately as focusing exclusively on AstraZeneca PLC's fundamentals will not take into account other important factors: AstraZeneca PLC Total Value Analysis
AstraZeneca PLC is at this time forecasted to have takeover price of 228.75 B with market capitalization of 194.87 B, debt of 22.96 B, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the AstraZeneca PLC fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
228.75 B | 194.87 B | 22.96 B |
AstraZeneca PLC Investor Information
About 48.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.36. AstraZeneca PLC last dividend was issued on the 23rd of February 2023. The entity had 2:1 split on the 27th of July 2015. Based on the measurements of operating efficiency obtained from AstraZeneca PLC's historical financial statements, AstraZeneca PLC is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.AstraZeneca PLC Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AstraZeneca PLC has an asset utilization ratio of 45.97 percent. This implies that the Company is making USD0.46 for each dollar of assets. An increasing asset utilization means that AstraZeneca PLC is more efficient with each dollar of assets it utilizes for everyday operations.AstraZeneca PLC Ownership Allocation
AstraZeneca PLC holds a total of 1.55 Billion outstanding shares. 30% of AstraZeneca PLC outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.AstraZeneca PLC Profitability Analysis
The company reported the revenue of 44.35 B. Net Income was 2.5 B with profit before overhead, payroll, taxes, and interest of 35.73 B.About AstraZeneca PLC Valuation
The stock valuation mechanism determines AstraZeneca PLC's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of AstraZeneca PLC based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of AstraZeneca PLC. We calculate exposure to AstraZeneca PLC's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AstraZeneca PLC's related companies.8 Steps to conduct AstraZeneca PLC's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates AstraZeneca PLC's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct AstraZeneca PLC's valuation analysis, follow these 8 steps:- Gather financial information: Obtain AstraZeneca PLC's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine AstraZeneca PLC's revenue streams: Identify AstraZeneca PLC's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research AstraZeneca PLC's industry and market trends, including the size of the market, growth rate, and competition.
- Establish AstraZeneca PLC's growth potential: Evaluate AstraZeneca PLC's management, business model, and growth potential.
- Determine AstraZeneca PLC's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate AstraZeneca PLC's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for AstraZeneca Stock Analysis
When running AstraZeneca PLC's price analysis, check to measure AstraZeneca PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AstraZeneca PLC is operating at the current time. Most of AstraZeneca PLC's value examination focuses on studying past and present price action to predict the probability of AstraZeneca PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AstraZeneca PLC's price. Additionally, you may evaluate how the addition of AstraZeneca PLC to your portfolios can decrease your overall portfolio volatility.